ammonium lysine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ammonium lysine
• 英文别名: Azane;2,6-diaminohexanoic acid；azane;2,6-diaminohexanoic acid
• 化学式: C₆H₁₄N₂O₂*H₃N
• 分子量: 163.22
• InChiKey: GBEYOWVXSWBVBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.43
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  93.2
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  DL-赖氨酸 在 ammonium hydroxide 作用下， 以 水 为溶剂， 生成 ammonium lysine
  参考文献：
  名称：

  一种有机金属盐添加剂的制备方法

  摘要：

  本发明公开一种有机金属盐添加剂的制备方法，步骤如下：（1）以短链有机酸为酸源，氨水为碱源，将两者在水溶液中混合，制备有机酸铵；（2）将铁源或者钙源或者锌源与步骤（1）所得溶液混合、搅拌、过滤、洗涤、干燥，得到高纯度的有机金属盐添加剂。本发明有机金属盐具有较好的晶型结构和较高的纯度，所用原材料来源广泛，价格低廉，较好地解决了现有工艺复杂、生产成本高和产率低等问题，具有良好的工业应用前景。

  公开号：

  CN111138271A

文献信息

• SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES
  申请人：Ohio State Innovation Foundation

  公开号：US20140155577A1

  公开（公告）日：2014-06-05

  Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nanotubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.

  揭示了与受保护或未受保护的氨基酸或肽连接的疏水药物的共轭物。所述的共轭物是两性的，可以自组装成纳米管。还描述了包含这些共轭物的纳米管，可以具有高药物载荷并保护药物免受降解或排泄。这些纳米管非常适合向个体输送疏水和不稳定的药物。
• [EN] BIOLOGICAL MATERIALS AND USES THEREOF<br/>[FR] MATÉRIELS BIOLOGIQUES ET LEURS UTILISATIONS
  申请人：ANTIKOR BIOPHARMA LTD

  公开号：WO2016046574A1

  公开（公告）日：2016-03-31

  The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5: 1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.

  该发明提供了包含治疗剂与载体分子偶联的化合物，最低偶联比为5:1；其中，载体分子是(i)抗体片段或其衍生物，或(ii)抗体模拟物或其衍生物；治疗剂偶联到赖氨酸氨基酸残基上；进一步，治疗剂不是光敏剂。还提供了关于这些化合物的用途、方法以及其制造过程。
• [EN] ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF<br/>[FR] LIEURS D'ACYLHYDRAZONE, PROCÉDÉS ET UTILISATIONS
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2019109188A1

  公开（公告）日：2019-06-13

  The present application is directed to compounds of Formula (I)-(VI): (I), (II), (III), (IV), (V) (VI), (VII) and (VIII), compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.

  目前的应用涉及公式(I)-(VI)的化合物：(I)、(II)、(III)、(IV)、(V)、(VI)、(VII)和(VIII)，包含这些化合物的组合物及其用途，例如作为药物和/或诊断剂。
• UNIVERSAL ENZYME RESPONSIVE LINKER FOR ASSEMBLING LIGANDS ON DNA FUNCTIONALIZED NANOMATERIALS
  申请人：University of Connecticut

  公开号：US20180258114A1

  公开（公告）日：2018-09-13

  Described herein is an enzyme-mediated approach to bioconjugation at nanoparticle (NP) surfaces. This process is enabled by a new synthetic linker compatible with the covalent attachment of alkyne modified substrates, including dyes, peptides and nucleic acids. The methods described herein specifically allow for the linkage of molecules to a DNA-functionalized nanoparticle surface. Enzymatic ligation of molecules to the terminal hydroxyl group of DNA using T4 DNA ligase is achieved through incorporation of a single monophosphate on the approaching substrate. In contrast to previous strategies, the linkers disclosed herein are compatible with alkyne modified molecules of a variety of sizes and charges indicating that the ligase minimally requires the monophosphate and the incoming hydroxyl for conjugation to be successful.

  本文描述了一种酶介导的方法，用于在纳米颗粒（NP）表面进行生物共轭。这一过程通过一种新的合成连接剂实现，该连接剂与炔改性底物（包括染料、肽和核酸）的共价结合兼容。本文所描述的方法特别允许将分子连接到DNA功能化的纳米颗粒表面。使用T4 DNA连接酶将分子酶接到DNA的末端羟基基团是通过在接近底物上引入单磷酸基团实现的。与先前的策略相比，本文披露的连接剂与各种大小和电荷的炔改性分子兼容，表明连接酶最少需要单磷酸基团和进入的羟基才能成功进行共轭。
• Antibody-Drug Conjugates, Compositions and Methods of Use
  申请人：Igenica Biotherapeutics, Inc.

  公开号：US20140363454A1

  公开（公告）日：2014-12-11

  Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.

  抗体-细胞毒素抗体药物偶联物及相关化合物，如连接剂-细胞毒素偶联物和用于制备它们的连接剂，管芽菌素类似物和其合成中间体；组合物；以及方法，包括治疗癌症的方法。